REGULATORY, PRESS RELEASE

THU, FEB 28, 2019 08:30 CET

Year-end report 2018

Intensified work with ChloraSolv.

JANUARY−DECEMBER 2018

  • Net sales amounted to SEK 2.6 million (2.3), a revenue growth of 12.1 percent.
  • Earnings before interest and taxes (EBIT) amounted to SEK -21.9 million (-19.3).
  • Earnings per share after dilution at SEK -0.36 (-0.34).
  • Cash flow from operating activities amounted to SEK -21.7 million (-15.9).
  • Cash flow from financing activities amounted to SEK +2.5 million (63.0).
  • Liquid assets at the end of the period at SEK 22.6 million (44.9).
  • Equity ratio was 84 percent (88).

OCTOBER−DECEMBER 2018

  • Net sales amounted to SEK 1.1 million (0.5), a revenue growth of 123.5 percent.
  • Earnings before interest and taxes (EBIT) amounted to SEK -5.9 million (-6.3).
  • Earnings per share after dilution at SEK -0.10 (-0.11).
  • Cash flow from operating activities amounted to SEK -5.0 million (-3.8).

NOTABLE EVENTS DURING THE FOURTH QUARTER

  • During November, the Swedish Medical Products Agency approved the new expanded clinical study for ChloraSolv on hard to heal foot- and legulcers with around 60 patients and the clinical study was initiated at the first site. The study name is ”ChloraSolv01”.
  • Eva Jagenheim, is appointed CFO, starting on 25th of March.
  • The wound-care patent, Dermasolv, is registered in the USA.
  • The Periimplantit patent is registered in Europe and in Japan.
  • The legal process deriving from a claim from a former co-worker, Karin Bergqvist, is ongoing.

IMPORTANT EVENTS AFTER THE PERIOD

  • First patients treated in ChloraSolv01.
  • Launch preparedness for ChloraSolv continues. We aim to participate at the EWMA event in Gothenburg in beginning of June.
  • At the turn of the year, the first commercial batches of Perisolv were produced at Biora AB. Also the new product ChloraSolv is now ready to be produced by our subcontractor.

TRADING PLACE AND CERTIFIED ADVISOR
RLS Global’s shares have been listed on the Nasdaq First North since 17th May, 2017 and trading takes place under the short name RLS. Certified Adviser is Erik Penser Bank, telephone +46 (0) 8 463 83 00, Email: certifiedadviser@penser.se. During the period 2012 – 2017, the company was listed on Aktietorget.

For more information, please contact:
Karin Fischer, CEO RLS Global AB,
+46 (0) 702 48 46 51, karin.fischer@rlsglobal.se

Eva Jagenheim, CFO RLS Global AB,
+46 (0)76 133 27 47, eva.jagenheim@rlsglobal.se

PUBLICATION
This information is such information that RLS Global AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the above contact person, at 8:30 CET on 28th February, 2019.

Press Release